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A B S T R A C T
Although mast cell distribution has been described in both human and canine hearts, cardiac mast cells in mice
have yet to be categorically localized. We therefore sought to describe mast cell distribution within the mouse
heart and characterize their dependence on the Microphthalmia-associated transcription factor (Mitf). Cardiac
mast cells were visualized using Toluidine Blue and avidin staining, and their distribution within the heart
described. Cardiac mast cells were most prevalent in the epicardium (50%) or myocardium (45%). Less fre-
quently, mast cells were noted in the endocardium (5%). Within the myocardium, 31% of the mast cells had
perivascular location. By studying two different Mitf mutant strains, Mitfmi-vga9 and MitfMi-wh, we demonstrated
that these mutations led to near-complete deficiency of cardiac mast cells. Accordingly, expression of the mMCP-
4 and mMCP-5 genes was lost and chymase enzyme activity was severely reduced. Additionally, hearts from mice
heterozygous for these Mitf mutations contained significantly fewer mast cells compared to wild-type mice. Our
results demonstrated that the distribution of cardiac mast cells in mice is different from humans and dogs.
Cardiac mast cells are dependent on Mitf expression, with loss-of-function mutation in the Mitf gene leading to
near-complete lack of cardiac mast cells. Loss of a single Mitf allele is sufficient for relative mast cell deficiency.
1. Introduction
Mast cells are primarily known for their role in allergic and ana-
phylactic reactions. However, studies have demonstrated that mast cells
have various other physiological and pathological effects in peripheral
tissues, including the heart (da Silva et al., 2014). Mast cells play an
important role in heart pathology and have been linked to various
cardiovascular diseases such as atherosclerosis, myocardial ischemia,
heart failure, and cardiac hypertrophy (Alevizos et al., 2014; Bot et al.,
2015; Hara et al., 2002; Reid et al., 2007). Importantly, the role of mast
cells differs depending on their location. This stems from the fact that
mast cell progenitors migrate to peripheral tissues, through organ-
specific migration pathways and it is the microenvironment of these
organs which stimulates mast cell differentiation (Gurish and Austen,
2012). In accordance with this, cardiac mast cells have been shown to
differ functionally from other organ-specific mast cells (Patella et al.,
1995). Whereas the distribution of cardiac mast cells has been de-
scribed in humans and dogs (Frangogiannis et al., 1999; Hellstrom and
Holmgren, 1950; Sperr et al., 1994), their distribution in mice is not
well characterized. This is unfortunate, as the mouse is the most widely
used genetic model of cardiac physiology and pathology.
Here, we describe the distribution of mast cells within the mouse
heart and compare it with mast cell distribution in other mammalian
species. The Microphthalmia-associated transcription factor (MITF) is a
basic helix-loop-helix leucine zipper master regulator that plays a cri-
tical role in the development of many cell types, including mast cells
(Hemesath et al., 1994; Steingrimsson et al., 2004). We examined
whether hearts from mice carrying two different Mitf mutations (Mitfmi-




C57BL/6 J, C57BL/6-Mitfmi-vga9 and C57BL/6-MitfMi-wh mice were
housed and bred in the animal facility at the University of Iceland. The
use of laboratory animals was approved by the Icelandic Food and
Veterinary Authority (permit ID: 2013-03-01). Maintenance and
handling of animals was performed in accordance with Icelandic and
European legislation on animal welfare.
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2.2. Histological staining and analysis
Mice were sacrificed and hearts fixed in formalin. Subsequently, the
hearts were embedded in paraffin and 4 μm thick sagittal sections ob-
tained, mounted, and stained with Toluidine Blue and avidin to vi-
sualize cardiac mast cells.
For avidin staining, the tissue sections were deparaffinized by xy-
lene and then rehydrated with ethanol twice for 5 minutes each. Next,
the slides were incubated in citrate buffer (p=6.0) for 20min at 95°
for antigen retrieval. After cooling, slides were treated with 10% fetal
bovine serum for 1 h at room temperature (RT). Subsequently, sections
were rinsed with immunofluoroscence (IF) buffer containing 0.15M
NaCl, 5 mM EDTA, 20mM HEPES, and 0.1% Triton X-100 (pH=7.5).
Sections were then stained with Alexa Fluor 488 conjugated avidin at
the dilution of 1:500 (Invitrogen, Austin, TX) and counterstained with
4′,6-diamidino-2-phenylindole (DAPI) 1:5000 (Sigma, St. Louis, MO)
diluted in IF buffer for 1 h at RT. Lastly, sections were rinsed twice with
IF buffer for 5min, once with distilled water, and coverslip added fol-
lowing dehydration.
For mast cell quantification, Toluidine Blue positive cells and avidin
positive cells were counted in two whole sections from each heart.
Using the Fiji software, area measurements were performed, and mast
cells quantified as cells per mm2 within different regions of the heart.
2.3. Enzyme activity assays
Mice were sacrificed and hearts snap frozen in liquid nitrogen.
Frozen hearts were put in 1mL of TrisHCl buffer containing 0.5M NaCl
and 1mM EDTA (pH=8.0) buffer along with 20 μL of aprotinin and
pulverized at 2600 rpm for 30 s. Sonication was thereafter performed
for 5min, followed by centrifugation at 14,000 rpm for 10min. The
supernatant was collected for analysis. Bradford assay was performed to
estimate protein amount and heart samples diluted in TrisHCl buffer,
containing 0.5M NaCl and 1mM EDTA (pH=8.0), to 2200 μg/mL
(Bradford, 1976).
For chymase activity assay, a solution containing 29.7 μL of 11mM
Suc-AAPF (Sigma-Aldrich, St. Louis, MO) and 240 μL of TrisHCl buffer
containing 0.5M NaCl and 1mM EDTA (pH=8.0) was prepared for
each sample and allowed to incubate for 10min. Thereafter, 60 μL of
sample was added and allowed to incubate for 10min, before adding
20 μL of 10mM chymostatin (Sigma-Aldrich) to stop the reaction.
Lastly, solutions were transferred to a 96 well plate (using 90 μL tri-
plicates from each sample) and absorbance measured at 405 nm using
EMax Plus Microplate Reader (Molecular Devices, Sunnyvale, CA).
Phosphatase activity assay was performed according to manu-
facturer’s suggestions with some modifications (Sigma-Aldrich). Briefly,
for each sample, 10 μL of 0.67 nM pNPP solution were added to 0.58mL
of diethanolamine buffer containing 0.50mM magnesium chloride
(pH=9.8), and allowed to incubate at 37° for 10min. Thereafter, 10 μL
of sample was added and allowed to incubate for 10min before the
reaction was stopped by adding 3M NaOH. Lastly, solutions were
transferred to a 96 well plate (using 150 μL triplicates for each sample)
and absorbance measured at 405 nm using EMax Plus Microplate
Reader (Molecular Devices, Sunnyvale, CA).
2.4. Quantitative real-time PCR
For quantitative real-time PCR, mice were sacrificed and hearts snap
frozen in liquid nitrogen. Hearts were pulverized twice at 2600 rpm for
30 s and RNA isolated according to protocol (Chomczynski and Sacchi,
1987). Next, cDNA was generated using Superscript II (Invitrogen) and
oligo(d)T primer mix. Real time PCR was performed using Power SYBR
Green PCR Master Mix (ThermoFisher Scientific, Waltham, MA). The
following primers were used for amplification: Actin sense, 5‘-CAC TGT
CGA GTC GCG TCC-3‘; Actin antisense, 5‘-TCA TCC ATG GCG AAC TGG
TG-3‘; Mitf sense, 5‘-AGC AAG AGC ATT GGC TAA AGA-3‘; Mitf anti-
sense, 3‘-GCA TGT CTG GAT CAT TTG ACT-‘5‘; mMCP-4 sense, 5‘-GCC
AAA GAG ACT CCC TCT GTG ATT-3‘; mMCP-4 antisense, 3‘-GCA TCT
CCG CGT CCA TAA GAT ACA-‘5‘; mMCP-5 sense, 5‘-CAC TGT GCG GGA
AGG TCT ATA ACA-3‘; mMCP-5 antisense, 3‘-TT ACT TCC TGC AGT
GTG TCG GAG-‘5‘.
2.5. Statistical analysis
All data are presented as mean ± SEM unless otherwise specified.
The Wilcoxon test was used to compare differences between two
groups. The Kruskal Wallis test was used to compare differences be-
tween multiple groups. The Conover test with Bonferroni correction
was used as a post hoc test. All statistical tests were two-tailed and a P
value less than 0.05 was considered significant.
3. Results
3.1. Distribution and localization of cardiac mast cells
To describe the location of mast cells within the heart, sagittal
sections from wild-type (C57BL/6 J) mouse hearts were obtained and
stained with Toluidine Blue in order to visualize mast cells. Mast cells
were quantified in the epicardium, myocardium, and endocardium of
the left and right ventricles and atria. Mast cells found within the heart
valves, aorta, pulmonary vessels, and the fibrous and parietal peri-
cardium were excluded from quantification since these were not con-
sistently present in the samples. The majority of mast cells were located
in the epicardium (Fig. 1a, e) or within the interstitium of the myo-
cardium (Fig. 1b, f). They were less frequently observed in the en-
docardium (Fig. 1c, g) or within the adventitia of myocardial arterioles
or venules (Fig. 1d, h). Within the myocardium, 31% of the mast cells
had perivascular location (Table 1).
When adjusted for area, mast cell density was more than twelvefold
higher in the epicardium than in the myocardium or endocardium,
Fig. 1. Distribution of mast cells within the
mouse heart. Mast cells visualized by Toluidine
Blue staining were most prevalent in a) the
epicardium and b) within the interstitium of
the myocardium. Mast cells were less fre-
quently found within c) the endocardium or d)
within the adventitia of myocardial arteries or
veins. e–h) High magnification images of the
boxed areas in a–d) are provided below. Scale
bars represent 200 μm in a–d) and 20 μm in
e–h) (For interpretation of the references to
colour in this figure legend, the reader is re-
ferred to the web version of this article).
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which had similar mast cell densities (8.29 ± 0.59 cells/mm2 vs
0.56 ± 0.05 cells/mm2 and 0.64 ± 0.09 cells/mm2 respectively)
(Table 2). When looking at the different chambers of the heart, mast
cell density was significantly higher in the atria as compared to the
ventricles (2.40 ± 0.46 cells/mm2 vs 1.03 ± 0.06 cells/mm2,
p=0.03). Furthermore, mast cell density was lowest in the septum
(0.52 ± 0.10 cells/mm2), and significantly higher in the right ventricle
as compared to the left ventricle (2.10 ± 0.25 cells/mm2 vs
1.09 ± 0.09 cells/ mm2, p < 0.001) (Table 2).
To confirm our findings, histological staining was performed using
avidin, a marker that has been demonstrated to bind mast cell granules
specifically (Tharp et al., 1985). Consistently, quantification of avidin
positive cells demonstrated similar mast cell distribution as described
above (Suppl. Table 1).
3.2. Mitf mutation leads to cardiac mast cell deficiency
Microphthalmia-associated Transcription Factor (MITF) is a basic
helix-loop-helix leucine zipper master regulator that plays a critical role
in mast cell differentiation (Qi et al., 2013). To assess the effects of Mitf
mutation on mast cell numbers in the heart we studied cardiac mast
cells in two different Mitf mutant alleles, Mitfmi-vga9 and MitfMi-wh. Sa-
gittal sections from hearts of wild-type (C57BL/6 J) mice as well as
hetero- and homozyogous B6-MitfMi-wh and B6-Mitfmi-vga9 mutant mice
were examined. The Mitfmi-vga9 mutant allele contains a transgene in-
sertion resulting in severely reduced expression of the Mitf mRNA
(Hodgkinson et al., 1993; Kataoka et al., 2002). The MitfMi-wh mutant
allele contains a point mutation that affects DNA binding but has little
effect on Mitf expression (Kataoka et al., 2002; Steingrimsson et al.,
1994). Homozygotes carrying the Mitfmi-vga9 mutation are characterized
by the absence of mast cells in the peritoneum, mesentery, and sto-
mach. Additionally, mast cell numbers in the skin are reduced to one
third of the number observed in the skin of wild type mice (Kataoka
et al., 2002; Morii et al., 2004a). Mast cells are absent from the peri-
toneum ofMitfMi-wh/MitfMi-whmice whereas their numbers are normal in
the mesentery and skin (Jippo et al., 2003; Kim et al., 1999; Morii et al.,
2004a). Cardiac mast cells were near absent from Mitfmi-vga9 and MitfMi-
wh homozygous mice and significantly fewer than in both heterozygotes
for each mutation and wild-type (Fig. 2a,c). Mice homozygous for the
MitfMi-wh mutation trended towards higher mast cell numbers than
Mitfmi-vga9 homozygous mice (0.09 ± 0.03 mast cells/mm2 vs
0.001 ± 0.001 mast cells/mm2, p=0.10). Interestingly, the number
of mast cells found inMitfmi-vga9/+ heterozygous hearts was reduced by
half as compared to wild-type hearts (0.54 ± 0.07 mast cells/mm2 vs
1.06 ± 0.06 mast cells/mm2, p < 0.001) (Fig. 3a). MitfMi-wh/+ het-
erozygotes had approximately two thirds of the number of mast cells
found in wild type hearts (0.71 ± 0.07 mast cells/mm2 vs
1.06 ± 0.06 mast cells/mm2, p=0.04). To confirm the reduction in
mast cell numbers in Mitf mutants, we performed avidin staining on
Mitfmi-vga9 hetero- and homozygotes. Consistently, avidin staining de-
monstrated near absence of cardiac mast cells in Mitfmi-vga9 homo-
zygotes (0.01±0.01 mast cells/mm2), and relative reduction in mast
cell numbers in Mitfmi-vga9 heterozygotes compared to wild-type hearts
(0.52±0.08 mast cells/mm2 vs 1.08±0.35 mast cells/mm2, p=0.04)
(Fig. 2b, d). Taken together, this demonstrates that Mitf is necessary for
normal cardiac mast cell numbers and that a single mutant allele is
sufficient for relative mast cell deficiency.
To estimate whether the reduced numbers of cardiac mast cells in
heterozygotes affected the distribution of mast cells within the heart,
we compared the mast cell distribution within different regions of the
heart between wild-type, Mitfmi-vga9/+, and MitfMi-wh/+ heterozygotes.
The mast cell distribution was generally similar in the three genotypes.
However, the percentage of mast cells within the septum of Mitf Mi-wh/
+ heterozygotes was significantly reduced compared to wild-type mice
(p= 0.03) (Table 1).
3.3. Chymase activity and expression is absent from Mitf mutant hearts
Chymase is a mast cell-specific serine protease that is commonly
used as a mast cell marker (Craig and Schwartz, 1989). Humans have a
single chymase gene, whereas mice have five. Real-time PCR was per-
formed to determine the expression of mMCP-4 and mMCP-5, the two
mouse chymases that are functionally and structurally closest to the
human chymase, respectively (Pejler et al., 2010). Our results demon-
strated severely reduced expression of both mMCP-4 and mMCP-5 in
homozygous Mitfmi-vga9 hearts compared to wild-type hearts
(p < 0.001 for both genes) (Fig. 3a,b). Additionally, mMCP-5 expres-
sion in heterozygous Mitfmi-vga9 hearts was significantly lower than in
wild-type hearts (p= 0.015). Similarly, mMCP-4 trended towards lower
expression in heterozygotes compared to wild-type hearts (p= 0.11).
Consistent with the effects of the Mitfmi-vga9 mutation, expression of Mitf
in the heart was absent from homozygotes and reduced to approxi-
mately 40% in heterozygotes as compared to wild type mice (Fig. 3c).
Chymase enzymatic activity was determined to evaluate whether
reduced chymase expression led to reduced functional activity of the
enzyme. Our results demonstrated that chymase activity was severely
reduced in Mitfmi-vga9/Mitfmi-vga9 hearts (Fig. 3d). Although chymase
activity was also reduced in heterozygotes, the difference was not sta-
tistically significant. Alkaline phosphatase activity was used as a control
measurement and no differences were observed between the three
groups (Fig. 3e). We conclude that there is a near-complete loss of
mature mast cells and mast-cell specific chymase in Mitfmi-vga9 mutant
mice.
4. Discussion
Mast cells have been linked to various cardiovascular diseases (Reid
et al., 2007). Here we demonstrate that mast cells distribution is
Table 1
Mast Cell Distribution in Wild-Type and Heterozygous Mitf Mutant Hearts.







Epicardium 50 ± 2 55 ± 5 56 ± 4
Myocardium 45 ± 2 43 ± 5 40 ± 4
Interstitial 69 ± 4 80 ± 7 75 ± 4
Perivascular 31 ± 4 20 ± 7 25 ± 4
Endocardium 5 ± 1 3 ± 2 4 ± 1
Atria 8 ± 2 11 ± 5 8 ± 3
Left ventricle 54 ± 3 59 ± 4 54 ± 4
Right ventricle 24 ± 2 31 ± 4 29 ± 2
Septum 14 ± 2 3+2* 9 ± 3
Asterisks denote statistical significance at P < 0.05 (*) compared to wild-type
mice.
a The mast cell proportion is calculated as the number of mast cells in a
particular region divided by the total number of mast cells in the heart.
Table 2
Mast Cells Density in Wild-Type Hearts.
Location WT
(n=21)
Epicardium 8.29 ± 0.59
Myocardium 0.56 ± 0.05
Endocardium 0.64 ± 0.09
Atria 2.40 ± 0.46
Left ventricle 1.09 ± 0.09
Right ventricle 2.10 ± 0.25
Septum 0.52 ± 0.10
Mast cell density is given as mast cells per mm2.
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different in mouse hearts, compared to humans. This is important as the
mouse remains the most widely used genetic model of human phy-
siology and pathology. Although the distribution of cardiac mast cells
has been described in humans and dogs (Frangogiannis et al., 1999;
Hellstrom and Holmgren, 1950; Sperr et al., 1994), this is to our best
knowledge the first time that mast cell distribution has been categori-
cally described in mouse hearts. Cardiac mast cells in mice are most
prominent within the epicardium (50%) and the myocardium (45%).
They are less frequently found within the endocardium (5%). When
adjusted for area, mast cell density is highest in the epicardium,
whereas it is lower but similar in the myocardium and the en-
docardium. The high density of epicardial mast cells is interesting since
it has not been described in other mammalian species. Although epi-
cardial mast cells in rats trend towards higher numbers compared to the
endocardium (Facoetti et al., 2006), the difference in mice is
twelvefold. Epicardial mast cells have also been described in humans
but they have not been quantified (Sperr et al., 1994). The mouse
myocardium and endocardium have approximately equal mast cell
densities, similar to human and canine hearts (Frangogiannis et al.,
1999; Sperr et al., 1994). Mast cell density in mice was found to be
significantly higher in atrial appendages compared to ventricles. This is
similar to humans but differs from dogs which have equal atrial and
ventricular densities (Frangogiannis et al., 1999; Sperr et al., 1994).
Taken together, this suggests that mast cell distribution is different
between mammalian species.
When looking at the different chambers of the heart, mast cell
density was greatest in the atria, followed by the right ventricle, left
ventricle, and interventricular septum in descending order. Since the
bulk of cardiac mast cells are located epicardially, this order is likely
due to higher proportion of epicardium within these regions of the
Fig. 2. Mif mutation leads to cardiac mast cell deficiency. A–B) Cardiac mast cells were identified using Toluidine Blue and avidin staining. The number of Toluidine
Blue and avidin positive cells are compared between wild-type mice and mice hetero- or homozygous for the Mitfmi-vga9 mutations. Arrows point to mast cells. Scale
bars represent 200 μm. For A) purple=Toluidine Blue. For B) green= avidin, blue=DAPI. C–D) Bar graphs comparing cardiac mast cell density in wild-type mice
and mice hetero- and homozygous for theMitf mi-vga9 andMitfMi-whmutations, using Toluidine Blue staining and avidin staining respectively. Both graphs demonstrate
near-complete lack of cardiac mast cells in homozygous Mitf mutant hearts, and significant reduction of mast cell numbers in heterozygotes compared to wild-type
mice. Asterisks denote statistical significance at P < 0.05 (*), and P < 0.001 (***) (For interpretation of the references to colour in this figure legend, the reader is
referred to the web version of this article).
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heart. Supporting this, the septum, which has no overlying epicardium,
has similar mast cell density as both the myocardium and endocardium.
In the current study, perivascular mast cells were defined as those found
within the adventitia of myocardial arterioles or venules. We found that
31% of mouse mast cells residing in the myocardium have periarteriolar
or perivenular location. For comparison, while 49% of canine cardiac
mast cells have been described as perivascular, 27% had periarteriolar
or perivenular location, which is consistent with our results.
In order to establish the role of cardiac mast cells in heart pathology
it is important to establish diverse models of cardiac mast cell defi-
ciency. Currently, only Kit-mutant and Cre/loxP-based mouse models
are available (Feyerabend et al., 2011; Kitamura et al., 1978). Although
Mitf mutant mice have been shown to have reduced numbers of mast
cells in both the peritoneum and the skin (Jippo et al., 2003; Kataoka
et al., 2002), the effect of Mitf in cardiac mast cells has not been
documented previously. Here we report that cardiac mast cells are Mitf
dependent and suggest that Mitf mutant mice may be a suitable model
for investigating mast cell function in the heart. In the current study,
mast cell deficiency in Mitf mutant hearts was demonstrated by Tolui-
dine Blue and avidin staining, and by loss of mast cell-specific chymase
activity and expression. This demonstrates that Mitfmi-vga9 and MitfMi-wh
homozygotes are cardiac mast cell depleted. Additionally, hearts from
Mitfmi-vga9/+ heterozygotes contained half the number of mast cells
found in wild-type hearts. Interestingly, MitfMi-wh/+ hearts trended
towards mast cell numbers closer to wild type hearts. Similarly, MitfMi-
wh/MitfMi-wh and MitfMi-wh/Mitfmi-vga9 mice, while both severely cardiac
mast cell deficient trended towards higher mast cell numbers than
Mitfmi-vga9 homozygotes. The Mitfmi-vga9 mutation leads to the absence of
Mitf expression (Hodgkinson et al., 1993), whereas the MitfMi-wh mu-
tation is less severe, with retained Mitf expression and reduced but
measurable DNA binding ability and nuclear localization (Kataoka
et al., 2002; Kim et al., 1999; Morii et al., 1994). This difference may
explain the higher mast cell numbers in the latter. Indeed, this has been
demonstrated in other tissues, such as the skin, where MitfMi-wh/MitfMi-
wh mice have normal mast cell numbers as opposed to Mitfmi-vga9/Mitfmi-
vga9mice which have reduced numbers (Kataoka et al., 2002).
In addition to guiding mast cell differentiation, MITF regulates the
expression of many mast cell-specific genes, including chymases.
Chymase is an angiotensin II-forming serine protease that is secreted
from mast cells following acute or chronic stimuli. In the Mitfmi-vga9
mutant heart both chymase expression and enzymatic activity is lost, as
expected. Additionally, hearts from Mitfmi-vga9/+ heterozygotes have
both reduced numbers of cardiac mast cells and reduced chymase ex-
pression compared to wild-type hearts. This suggests that both alleles of
Mitf are required for normal cardiac mast cell numbers. Since Mitf plays
a key role in mast cell development, the loss of cardiac mast cells inMitf
mutants is likely due to failure of mast cell differentiation.
Alternatively, it may be explained by defective migration. As mast cell
precursor cells migrate from the bone marrow and differentiate in their
target environment, it is possible that the local environment affects
cardiac mast cell localization. Supporting this, Mitf is not only ex-
pressed in mast cells in the heart, but also cardiomyocytes and valvular
melanocytes (Tshori et al., 2007; Yajima and Larue, 2008). A study
examining the role of Mitf in mast cell development demonstrated that
bone marrow transplantation from a wild-type host to an Mitfmi-vga9
homozygote recipient led to reduced mast cell density in skin, perito-
neum, mesentery, stomach, and spleen. Interestingly, transplantation of
Mitfmi-vga9 homozygous bone marrow cells to W/Wv mice, a strain with
mast cell deficiency but normal tissue environment, also led to reduced
mast cell density (Morii et al., 2004b). Consistently, the cardiac mast
cell deficiency observed in our study may be due to combination of both
defective intracellular pathways in mast cell precursor cells and
changes in the local environment.
The loss of cardiac mast cells and chymase activity has major im-
plications for heart pathology. Chymase, angiotensin I converting en-
zyme (ACE), and cathepsin G all degrade Angiotensin I (Ang I) to
Fig. 3. Chymase activity and expression is absent from Mitf mutant hearts. a–c) Expression of mMCP4, mMCP5 and MITF in wild-type (WT), and hetero- and
homozygous Mitfmi-vga9 mutant hearts. Expression of all genes was significantly reduced in homozygous Mitfmi-vga9 mutant hearts compared to wild-type and het-
erozygous Mitfmi-vga9/+ hearts. d–e) Chymase and phosphatase activity assays in wild-type, hetero- and homozygous Mitfmi-vga9 mutant hearts. Chymase activity was
significantly reduced in homozygous Mitfmi-vga9 mutant hearts compared to wild-type hearts. Phosphatase activity was similar between all genotypes. Red bars
represent median value for each genotype. Asterisks denote statistical significance at P < 0.05 (*), and P < 0.001 (***) (For interpretation of the references to
colour in this figure legend, the reader is referred to the web version of this article).
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Angiotensin II (Ang II). In the blood, circulating serine protease in-
hibitors restrict chymase and cathepsin G activity (Tojo and Urata,
2013). Ang II formation is therefore mostly contributed by ACE activity
in the blood, while chymase seems to be the principal Ang II forming
enzyme in the heart (Urata et al., 1993). Mast cell derived-chymase has
been linked to a role in various cardiovascular diseases, such as
atherosclerosis, arrhythmias, heart failure, and hypertrophy (Reid et al.,
2007). As well as being the key Ang II-forming enzyme in the heart,
chymase directly induces activation of TGF-β (Lindstedt et al., 2001).
TGF-β has been shown to be a downstream mediator of Ang II-induced
cardiac hypertrophy (Schultz et al., 2002). Furthermore, chymase in-
duces extracellular matrix degradation, cardiomyocyte apoptosis, and
fibroblast proliferation (Hara et al., 1999; Janicki et al., 2006). These
are all key characteristics in hypertrophy of failing hearts. Cardiac
hypertrophy occurs in response to increased cardiac load. Interestingly,
Mitf is required for cardiac hypertrophy in response to β-adrenergic or
Ang II stimulation in mice, and Mitf mutant hearts fail to appropriately
respond to these hypertrophic stimuli (Liu et al., 2014; Tshori et al.,
2006). There is added complexity due to the fact that in the heartMitf is
not only expressed in mast cells but in cardiomyocytes as well. In fact,
Mitf has been shown to induce cardiac hypertrophy through negatively
regulating mi-R541 expression in cardiomyocytes (Liu et al., 2014).
This hypertrophic response was induced by Ang II treatment, which, as
stated above, is primarily generated by chymase (Urata et al., 1993).
Based on the complete loss of chymase activity in the Mitfmi-vga9 mutant
heart we suggest that the role of Mitf in inducing cardiac hypertrophy
is, at least in part, mast cell and chymase dependent.
Our results must be interpreted in the context of several limitations.
First, as mast cells differentiate in their target environment, we cannot
exclude the possibility that cardiac mast cell progenitor cells, that do
not contain granules or express the major mast cell proteases, may be
present in Mitf mutant mice. If so, they are unlikely to be functional as
mast cells. Second, all quantification and distribution measurements
were acquired using sagittal sections. It is possible that mast cell loca-
lization differs in lateral sections. Whole mount staining may be per-
formed for better visualization of mast cells within the whole heart.
Lastly, our distribution analysis was gathered by studying C57BL/6 J
mice, the most commonly used inbred mouse strain. Further analysis of
different mouse strains is needed to determine whether the distribution
observed is specific to the C57BL/6 J strain.
5. Conclusions
Our results demonstrate that the distribution of cardiac mast cells in
mice is different from humans and dogs. This is particularly important
since mice remain the most widely used animal model for cardiac pa-
thology and physiology. The different cellular composition of mam-
malian hearts must be considered when basic research from animal
models is translated to clinical settings. In addition, we demonstrate
that cardiac mast cells are Mitf dependent, with loss-of-function muta-
tion in the Mitf gene leading to near-complete lack of mature cardiac
mast cells.
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